川崎病患儿树突状细胞亚群变化及意义初探

doi:10.12372/jcp.2022.21e1680

临床儿科杂志 ›› 2022, Vol. 40 ›› Issue (7): 500-504.doi: 10.12372/jcp.2022.21e1680

川崎病患儿树突状细胞亚群变化及意义初探

王娜娜¹, 孟丽君², 张欠文³, 张帆¹, 侯淼¹, 陈烨¹, 王波¹, 严文华¹, 吕海涛¹, 孙凌¹, 黄洁¹()

1.苏州大学附属儿童医院心内科,（江苏苏州 215025）
2.苏州大学附属儿童医院血液科,（江苏苏州 215025）
3.苏州大学附属儿童医院呼吸内科,（江苏苏州 215025）

收稿日期:2021-12-06 出版日期:2022-07-15 发布日期:2022-07-08
通讯作者: 黄洁 E-mail:j.shuang@163.com
基金资助:
苏州市姑苏卫生人才培养项目(No.GSWS2019015);苏州市科技发展计划(No.SKJY2021108);江苏省研究生科研创新计划(No.KYCX20-2725)

Changes and significance of dendritic cell subsets in children with Kawasaki disease

WANG Nana¹, MENG Lijun², ZHANG Qianwen³, ZHANG Fan¹, HOU Miao¹, CHEN Ye¹, WANG Bo¹, YAN Wenhua¹, LYU Haitao¹, SUN Ling¹, HUANG Jie¹()

1. Department of Cardiology,Children’s Hospital of Soochow University, Suzhou 215025, Jiangsu, China
2. Department of Hematology,Children’s Hospital of Soochow University, Suzhou 215025, Jiangsu, China
3. Department of Respiratory Disease, Children’s Hospital of Soochow University, Suzhou 215025, Jiangsu, China

Received:2021-12-06 Online:2022-07-15 Published:2022-07-08
Contact: HUANG Jie E-mail:j.shuang@163.com

摘要/Abstract

摘要：

目的探讨急性期川崎病（KD）患儿外周血树突状细胞（DC）亚群的变化及意义。方法回顾性分析2020年12月—2021年5月就诊的初发急性期KD患儿的临床资料。KD患儿分别于静脉注射用免疫球蛋白（IVIG）治疗前、后取血,采用流式细胞术检测外周血DC亚群浆细胞样树突状细胞（pDC）及CD1c⁺髓样树突状细胞（mDC）数量和比例及表面功能分子HLA-DR、CD86、CD40蛋白表达水平。选择同期健康体检儿童作为对照组。结果 KD组患儿32例,男19例、女13例,中位年龄37.0（22.3~58.5）月。对照组23例,男14例、女9例,中位年龄52.0（30.0~65.0）月。KD组患儿IVIG治疗前、治疗后的pDC、CD1c⁺mDC占外周血总DC比例均低于对照组,治疗后组CD1c⁺mDC占外周血总DC比例高于治疗前;治疗前组pDC、CD1c⁺mDC数量低于对照组和治疗后组,差异均有统计学意义（P<0.05）。治疗前组pDC表面CD86、CD40表达以及CD1c⁺mDC表面HLA-DR、CD86水平均低于对照组和治疗后组,差异有统计学意义（P<0.05）。急性期KD患儿pDC和CD1c⁺mDC数量与C反应蛋白、中性粒细胞与淋巴细胞比值均呈显著负相关（P<0.05）;CD1c⁺mDC细胞数量与血沉也呈显著负相关（P<0.05）。结论 KD患儿外周血循环中pDC和CD1c⁺mDC存在数量不足及功能受损,pDC和CD1c⁺mDC可能参与了KD的发病过程。

关键词: 川崎病, 树突状细胞, 抗原提呈分子, 共刺激分子

Abstract:

Objective To investigate the changes of dendritic cell (DC) subsets in children with acute Kawasaki disease (KD) and their significance. Methods The clinical data of children with initial acute KD from December 2020 to May 2021 were retrospectively analyzed. Blood samples of KD children were taken before and after intravenous immunoglobulin (IVIG) treatment. Flow cytometry was used to detect the number and proportion of DC subgroup plasmacytoid dendritic cells (pDC) and CD1c⁺ myeloid dendritic cells (mDC) in peripheral blood as well as the expression levels of human leucocyte antigen-DR (HLA-DR), CD86 and CD40 proteins. Children who underwent physical examination at the same period were selected as the control group. Results There were 32 children (19 boys and 13 girls) in the KD group, and the median age was 37.0 (22.3-58.5) months. In the control group, there were 23 children (14 boys and 9 girls) and the median age was 52.0 (30.0-65.0) months. The proportion of pDC and CD1c⁺mDC in peripheral blood DCs before and after IVIG treatment in KD group was lower than that in control group, and the proportion of CD1c⁺mDC in peripheral blood DCs after treatment was higher than that before treatment. The number of pDC and CD1c⁺mDC in pre-treatment group was lower than that in control group and post-treatment group, and the differences were statistically significant (P<0.05). The expression levels of CD86 and CD40 on pDC surface and the expression levels of HLA-DR and CD86 on CD1c⁺mDC surface were lower than those in control group and post-treatment group, with statistical significance (P<0.05). The number of pDC and CD1c⁺mDC in KD children in acute stage was significantly negatively correlated with c-reactive protein and neutrophil to lymphocyte ratio (P<0.05). The number of CD1c⁺mDC was also negatively correlated with ESR (P<0.05). Conclusions The number of pDC and CD1c⁺mDC in peripheral blood circulation of KD children was insufficient and their function was impaired. Circulating pDC and CD1c⁺mDC may be involved in the immunological pathogenesis of KD.

Key words: Kawasaki disease, dendritic cell, antigen-presenting molecule, costimulatory molecule

王娜娜, 孟丽君, 张欠文, 张帆, 侯淼, 陈烨, 王波, 严文华, 吕海涛, 孙凌, 黄洁. 川崎病患儿树突状细胞亚群变化及意义初探[J]. 临床儿科杂志, 2022, 40(7): 500-504.

WANG Nana, MENG Lijun, ZHANG Qianwen, ZHANG Fan, HOU Miao, CHEN Ye, WANG Bo, YAN Wenhua, LYU Haitao, SUN Ling, HUANG Jie. Changes and significance of dendritic cell subsets in children with Kawasaki disease[J]. Journal of Clinical Pediatrics, 2022, 40(7): 500-504.

图/表 3

图1

表1

表2

参考文献 15

[1]	Fukazawa R, Kobayashi J, Ayusawa M, et al. JCS/JSCS 2020 guideline on diagnosis and management of cardiovascular sequelae in Kawasaki disease[J]. Circ J, 2020, 84(8): 1348-1407. doi: 10.1253/circj.CJ-19-1094
[2]	Kainth R, Shah P. Kawasaki disease: origins and evolution[J]. Arch Dis Child, 2021, 106(4): 413-414.
[3]	Zhou C, Zhao Y, Wang X, et al. Laboratory parameters between multisystem inflammatory syndrome in children and Kawasaki disease[J]. Pediatr Pulmonol, 2021, 56(12): 3688-3698. doi: 10.1002/ppul.25687
[4]	Schulte D, Yilmaz A, Shimada K, et al. Involvement of innate and adaptive immunity in a murine model of coronary arteritis mimicking Kawasaki disease[J]. J Immunol, 2009, 183(8): 5311-5318. doi: 10.4049/jimmunol.0901395 pmid: 19786535
[5]	Yilmaz A, Rowley A, Schulte DJ, et al. Activated myeloid dendritic cells accumulate and co-localize with CD3⁺ T cells in coronary artery lesions in patients with Kawasaki disease[J]. Exp Mol Pathol, 2007, 83(1): 93-103. doi: 10.1016/j.yexmp.2007.01.007
[6]	Eisenbarth SC. Dendritic cell subsets in T cell programming: location dictates function[J]. Nat Rev Immunol, 2019, 19(2): 89-103. doi: 10.1038/s41577-018-0088-1 pmid: 30464294
[7]	Wculek SK, Cueto FJ, Mujal AM, et al. Dendritic cells in cancer immunology and immunotherapy[J]. Nat Rev Immunol, 2020, 20(1): 7-24. doi: 10.1038/s41577-019-0210-z
[8]	Wu M, Gao L, He M, et al. Plasmacytoid dendritic cell deficiency in neonates enhances allergic airway inflammation via reduced production of IFN-α[J]. Cell Mol Immunol, 2020, 17(5): 519-532.
[9]	McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association[J]. Circulation, 2017, 135(17): e927-e999.
[10]	Reizis B. Plasmacytoid dendritic cells: development, regulation, and function[J]. Immunity, 2019, 50(1): 37-50. doi: S1074-7613(18)30575-2 pmid: 30650380
[11]	Chang A, Islam S. Kawasaki disease and vasculitis associated with immunization[J]. Pediatr Int, 2018, 60(7): 613-617. doi: 10.1111/ped.13590
[12]	Burns JC, Song Y, Bujold M, et al. Immune-monitoring in Kawasaki disease patients treated with infliximab and intravenous immunoglobulin[J]. Clin Exp Immunol, 2013, 174(3): 337-344. doi: 10.1111/cei.12182 pmid: 23901839
[13]	Kim HY, Lee HG, Kim DS. Apoptosis of peripheral blood mononuclear cells in Kawasaki disease[J]. J Rheumatol, 2000, 27(3): 801-806. pmid: 10743828
[14]	Dress RJ, Wong AY, Ginhoux F. Homeostatic control of dendritic cell numbers and differentiation[J]. Immunol Cell Biol, 2018, 96(5): 463-476. doi: 10.1111/imcb.12028
[15]	Hwang SY, Shin TG, Jo IJ, et al. Neutrophil-to-lymphocyte ratio as a prognostic marker in critically-ill septic patients[J]. Am J Emerg Med, 2017, 35(2): 234-239. doi: S0735-6757(16)30750-1 pmid: 27806894

组别	例数	pDC/%	CD1c⁺mDC/%	pDC/个·mL^-1	CD1c⁺mDC/个·mL^-1
对照组	23	46.8(34.1~58.2)	33.3(26.6~40.5)	19 032.0(14 296.0~28 642.0)	14 592.0(8 889.0~18 059.0)
治疗前组	32	26.3(16.0~39.6)¹⁾	10.1(7.4~17.8)¹⁾	9 449.0(4 821.0~22 561.0)¹⁾	4 747.0(2 245.0~6 628.0)¹⁾
治疗后组	32	33.1(26.8~41.5)¹⁾	17.9(13.9~27.0)¹⁾²⁾	19 307.0(11 632.0~26 346.0)²⁾	10 604.0(6 488.0~149 650.0)²⁾
H值		16.66	26.53	11.36	22.91
P		<0.001	<0.001	0.003	<0.001

组别	例数	pDC			CD1c⁺ mDC
组别	例数	HLA-DR	CD86	CD40	HLA-DR	CD86	CD40
对照组	23	15 057.0 (12 398.0~18 301.0)	295.0 (224.0~397.0)	488.0 (376.0~725.0)	24 552.0 (18 513.0~28 455.0)	1 459.0 (1 389.0~1 576.0)	297.0 (247.0~389.0)
治疗前组	32	14 384.0 (9 243.0~18 244.0)	213.0 (142.0~258.0)¹⁾	275.0 (248.0~403.0)¹⁾	17 583.0 (13 912.0~22 127.0)¹⁾	885.0 (825.0~1 074.0)¹⁾	328.0 (276.0~477.0)
治疗后组	32	15 249.0 (12 303.0~18 505.0)	262.0 (184.0~344.0)²⁾	457.0 (326.0~529.0)²⁾	22 624.0 (17 504.0~27 877.0)²⁾	1 123.0 (965.0~1 342.0)¹⁾²⁾	343.0 (252.0~474.0)
H值		1.17	10.16	21.15	13.42	42.18	3.28
P		0.559	0.006	<0.001	0.001	<0.001	0.195

川崎病患儿树突状细胞亚群变化及意义初探

Changes and significance of dendritic cell subsets in children with Kawasaki disease

RichHTML

PDF (PC)

赞

可视化

摘要/Abstract

引用本文

使用本文

图/表 3

参考文献 15

相关文章 15

Metrics

本文评价

推荐阅读 0

[1]	黄敏. 单细胞测序技术在川崎病研究中的应用现状[J]. 临床儿科杂志, 2023, 41(7): 481-485.
[2]	郝胜, 黄敏. 儿童川崎病相关巨噬细胞活化综合征的临床诊治[J]. 临床儿科杂志, 2023, 41(7): 486-491.
[3]	刘芳, 林怡翔. 川崎病严重冠状动脉病变的长期管理[J]. 临床儿科杂志, 2023, 41(7): 492-497.
[4]	周翠臻, 宋思瑞, 陈丽琴, 黄敏. 川崎病合并冠状动脉瘤危险因素分析[J]. 临床儿科杂志, 2023, 41(7): 498-501.
[5]	徐丹, 潘冬宁, 李亚琴. 川崎病患儿血清五聚蛋白-3水平对静脉注射免疫球蛋白抵抗的影响和预测价值[J]. 临床儿科杂志, 2023, 41(7): 502-506.
[6]	何方园, 何学华, 袁勇华, 朱柳蓉, 吴意, 夏晓辉. 川崎病急性期血脂与年龄、冠状动脉病变及严重程度的关系[J]. 临床儿科杂志, 2023, 41(6): 455-458.
[7]	邱佳韵（综述）, 周国平（审校）. 川崎病冠状动脉损伤机制免疫遗传研究进展[J]. 临床儿科杂志, 2023, 41(1): 66-72.
[8]	孙蕊, 曹爱梅, 李晓惠, 袁越, 张明明, 李丹, 石琳. 基于超声心动图评估儿童川崎病冠状动脉异常的方法分析[J]. 临床儿科杂志, 2022, 40(9): 690-695.
[9]	黄玉娟, 黄敏. 川崎病静脉注射丙种球蛋白无反应预测模型研究现状[J]. 临床儿科杂志, 2022, 40(7): 481-487.
[10]	刘蕾，宋晓翔，封其华. 川崎病合并关节炎 2 例报告并文献复习[J]. 临床儿科杂志, 2022, 40(1): 58-.
[11]	高微微，邹映雪. 川崎病休克综合征早期识别与诊治研究进展[J]. 临床儿科杂志, 2021, 39(3): 237-.
[12]	邓海梅, 闵丽, 吴瑾志, 等. 川崎病合并胰腺炎和低T3综合征1例报告[J]. 临床儿科杂志, 2021, 39(10): 733-.
[13]	张海洋,罗黎力,李德渊,等. 川崎休克综合征致急性肾损伤1例报告[J]. 临床儿科杂志, 2021, 39(10): 736-.
[14]	王亮. 类川崎病——儿童多系统炎症综合征诊疗相关研究现状[J]. 临床儿科杂志, 2021, 39(10): 792-.
[15]	王复娟，吴良霞. 川崎病冠状动脉损害相关危险因素分析[J]. 临床儿科杂志, 2020, 38(7): 481-.